Simoes, AR, González, SC, Lopez-Doldan, MD, Duran, G, Fernández-Montes, A, Fernandez, MP, Fernandez, MS, Mata, JG, Paez, D, Riera, P, Guino, E, Lopez-Fernandez, L, de Santiago, BG, Aspiroz, EL, Rojas, A, Castells, A, Castellvi-Bel, S, Ponte, CR, Vymetalkova, V, Carracedo, A, Fernandez-Rozadilla, C. Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer. BRITISH JOURNAL OF PHARMACOLOGY. 2025; 182(21)DOI:10.1111/bph.70051. PMID:40624839. IF:7.700(Q1/1D).

Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108763. PMID:41033130. IF:4.400(Q1/2D).

Soler, G, Grávalos, C, Rivera, F, Safont, MJ, Virgili, AC, Valladares-Ayerbes, M, Ferreiro-Monteagudo, R, Ortiz-Morales, MJ, Polo-Marques, E, Kornusova-Bersheva, I, Soustre, E, Yao, WY, Élez, E. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03907-z. PMID:40338282. IF:2.500(Q3/6D).

Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108799. PMID:41108882. IF:4.400(Q1/2D).

Volta-Durán, E, Sánchez, JM, Favaro, MTP, Martinez-Cuentra, G, Contreras, E, di Somma, A, López-Laguna, H, Unzueta, U, Casanova, I, Mangues, R, Villaverde, A, Vázquez, E. Self-disintegrating protein-leaking microparticles for topical protein delivery. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 2025; 329DOI:10.1016/j.ijbiomac.2025.147730. PMID:40967544. IF:8.500(Q1/1D).

Carrasco-Díaz, LM, Otero-Mateo, M, Alamo, P, Gallardo, A, Virgili, AC, Páez, D, Voltà-Durán, E, Villaverde, A, Vázquez, E, Unzueta, U, Casanova, I, Alba-Castellon, L, Mangues, R. Nanotoxin induces in situ pyroptosis to sensitize aPD1 to ablate metastases in microsattellite stable colorectal cancer. PHARMACOLOGICAL RESEARCH. 2025; 221DOI:10.1016/j.phrs.2025.107982. PMID:41083088. IF:10.500(Q1/1D).

Sansa, A, Vásquez, R, Valero, C, Vázquez, C, Holgado, A, Gayà, J, Rubio, D, León, X. Prognostic value of pretreatment peripheral blood biomarkers in patients with head and neck squamous cell carcinoma treated with chemo/bioradiotherapy. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03897-y. PMID:40323571. IF:2.500(Q3/6D).

Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).

Grasa, E, Forment, A, Alonso-Solís, A, Ramalho, L, Roldán, A, Pousa, E, Aussó, S, Berdun, J, Tesoro, AG, Escudero, J, Corripio, I. Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia. ACTAS ESPANOLAS DE PSIQUIATRIA. 2025; 53(6)DOI:10.62641/aep.v53i6.1959. PMID:41437755. IF:1.600(Q3/7D).

Serra-Lopez, J, Miranda, A, Soria, A, Lopez, N, Castañon, E, Majem, M. Clinical practice guide for nurses that optimizes nurse's comprehensive care of patients undergoing immunotherapy. Enfermeria Clinica. 2025; 35(6)DOI:10.1016/j.enfcle.2025.502193. PMID:40204238. IF:(Q/D).

Miró, O, Ivars, N, Espinosa, B, Jacob, J, Alquézar-Arbé, A, Gil, V, Bellido, A, Serrano, L, Herrero-Puente, P, Fortuny, MJ, Mir, M, Soy, E, Esquivias, MA, Tost, J, Travería, L, Domingo, E, Noceda, J, López-Diez, MP, Aguirre, A, Alonso, H, Romero, M, López-Grima, ML, López, ML, Mueller, C, Peacock, WF, Puente, PH. Use of nebulized bronchodilators in acute heart failure: impact on outcomes. Internal and Emergency Medicine. 2025; 20(8)DOI:10.1007/s11739-025-04123-x. PMID:41162690. IF:3.800(Q1/2D).

Gómez-Hidalgo, NR, Cabrera, S, Bebia, V, García-Pineda, V, Padilla-Iserte, P, Fabregas, FF, Fuste, P, Alonso, P, Rodriguez, TG, Fernandez-Gonzalez, S, Chacon, E, Alvarez, JAP, Oliver, R, Gil-Moreno, A. The MULTISENT Study: A Multicenter Study on the Detection Rate of Sentinel Lymph Node Mapping in Endometrial Cancer Across Spain. ANNALS OF SURGICAL ONCOLOGY. 2025; 32(12)DOI:10.1245/s10434-025-17836-2. PMID:40702200. IF:3.500(Q1/2D).

Martinez-Brocca, Maria Asuncion, Bellido, Virginia, Cardona-Hernandez, Roque, Castaño, Luis, Conget, Ignacio, Fernandez, Alberto, Gomez Gila, Ana Lucia, Leiva-Gea, Isabel, Mauricio, Didac. Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: consensus of the scientific societies SED, SEEN and SEEP.. Anales De Pediatria. 2025; 103(5)DOI:10.1016/j.anpede.2025.503944. PMID:. IF:(Q/D).

Llao, J, Mañosa, M, Martín-Arranz, E, Zabana, Y, Navarro-Llavat, M, Téller, M, Garcia-Planella, E, Busquets, D, Monfort, D, Pineda, JR, Gutiérrez, A, Villoria, A, Menchén, L, Bastida, G, García-Alonso, FJ, Rivero, M, Chaparro, M, de Francisco, R, Merino, O, Rodríguez-Lago, I, Acosta, MBD, Rodríguez-Fortúnez, P, Rodríguez-Jiménez, C, Calafat, M, Domènech, E. Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU. Journal of Crohns & Colitis. 2025; 19(11)DOI:10.1093/ecco-jcc/jjaf182. PMID:41258993. IF:8.700(Q1/1D).

Vega-Abellaneda, S, Román, E, Soler, Z, Ortiz, MA, Rossi, G, Biagini, L, Sánchez, E, Pons-Tarin, M, Laghi, L, Mengucci, C, Kaur, N, Poca, M, Cuyàs, B, Serrano-Gomez, G, Alvarado, E, Manichanh, C, Soriano, G. A Metagenomics Approach to Frailty in Patients With Cirrhosis Undergoing a Multifactorial Intervention. LIVER INTERNATIONAL. 2025; 45(12)DOI:10.1111/liv.70418. PMID:41174950. IF:5.200(Q1/2D).

Melmed, S, di Filippo, L, Fleseriu, M, Mercado, M, Karavitaki, N, Gurnell, M, Salvatori, R, Tsagarakis, S, Losa, M, Maffei, P, Pereira, AM, Geer, EB, Katznelson, L, van der Lely, AJ, Bollerslev, J, Esposito, D, Webb, SM, Zatelli, MC, Valassi, E, Neggers, S, Chanson, P, Ho, KKY, Ioachimescu, AG, Biller, BMK, Samson, SL, Kaiser, UB, Schilbach, K, Luque, RM, Casanueva, FF, Shimon, I, Boguszewski, CL, Biermasz, N, Colao, A, Pirchio, R, Lamberts, SWJ, Kadioglu, P, Buchfelder, M, Frara, S, Chiloiro, S, Petersenn, S, Gadelha, MR, Puig-Domingo, M, Luger, A, Brue, T, Beckers, A, Ferone, D, Clemmons, DR, Greenman, Y, Marazuela, M, Mortini, P, Strasburger, CJ, Giustina, A. Consensus on acromegaly therapeutic outcomes: an update. Nature Reviews Endocrinology. 2025; 21(11)DOI:10.1038/s41574-025-01148-2. PMID:40804505. IF:40.000(Q1/1D).

Portu, M, Martinez-Recio, S, Barba, A, Gonzalez, A, López, L, Catasús, L, Majem, M. First-Line Osimertinib in a Patient Having NSCLC With a Rare Duplication Mutation in the EGFR Exon 19 Region (NM_005228.5:c.2214_2231dup p.(Ile740_Lys745dup)). Clinical Lung Cancer. 2025; 26(7)DOI:10.1016/j.clic.2025.07.013. PMID:40774920. IF:3.300(Q2/4D).

Cardozo, AR, Tibau, A, Liu, I, Han, J, Cliff, E, Kesselheim, A. Assessing outcomes emerging after confirmatory trials of accelerated approval drugs, 1992-2021. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2894. PMID:. IF:65.400(Q1/1D).

Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).

Martin-Broto, J, Ospina, GM, Garcia, AS, Trufero, JM, Martinez-Garcia, J, Fidalgo, JAP, Morales, CMV, Jurado, JC, Ledesma, P, Grifman, M, Moura, DD, Muñiz, NH. CIRTUSARC: A multicenter, open-label phase II trial of cirtuvivint as second-line therapy in selected advanced soft-tissue sarcomas. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3354. PMID:. IF:65.400(Q1/1D).